Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study [Original Articles]

Conclusions In patients with nonobstructive HCM, ranolazine showed no overall effect on exercise performance, plasma prohormone brain natriuretic peptide levels, diastolic function, or quality of life. The drug showed an excellent safety profile and was associated with reduced premature ventricular complex burden. Late sodium current inhibition does not seem to improve functional capacity in HCM. Clinical Trial Registration: URL: https://www.clinicaltrialsregister.eu. Unique identifier: 2011-004507-20

http://circheartfailure.ahajournals.org/cgi/content/short/11/1/e004124?rss=1

Source: Circulation: Heart Failure - January 10, 2018 Category: Cardiology Authors: Olivotto, I., Camici, P. G., Merlini, P. A., Rapezzi, C., Patten, M., Climent, V., Sinagra, G., Tomberli, B., Marin, F., Ehlermann, P., Maier, L. S., Fornaro, A., Jacobshagen, C., Ganau, A., Moretti, L., Hernandez Madrid, A., Coppini, R., Reggiardo, G., P Tags: Clinical Studies, Cardiomyopathy Original Articles Source Type: research